Prevalence of persistent symptoms at least 1 month after SARS-CoV-2 Omicron infection in adults

被引:5
|
作者
Gallant, Maxime [1 ]
Mercier, Kassandra [1 ]
Rioux-Perreault, Christine [1 ]
Lemaire-Paquette, Samuel [1 ]
Piche, Alain [1 ,2 ]
机构
[1] Clin Res Ctr Hosp Univ Sherbrooke CRCHUS, Sherbrooke, PQ, Canada
[2] Univ Sherbrooke, Dept Microbiol & Infectiol, Sherbrooke, PQ, Canada
来源
JOURNAL OF THE ASSOCIATION OF MEDICAL MICROBIOLOGY AND INFECTIOUS DISEASE CANADA (JAMMI) | 2022年 / 8卷 / 01期
关键词
BQC19; COVID-19; Omicron variant; post-COVID-19; condition; prevalence; vaccination;
D O I
10.3138/jammi-2022-0026
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Persistent post-COVID-19 symptoms pose an important health care burden. The Omicron variant has rapidly spread across the world and infected millions of people, largely exceeding previous variants. The potential for many of these people to develop persistent symptoms is a major public health concern. The aim of this study was to determine the prevalence and risk factors of post-COVID-19 symptoms associated with Omicron.Methods: We conducted a single-centre prospective observational study in Quebec, Canada, between December 2021 and April 2022. Participants were adults enrolled in the Biobanque Qu & eacute;b & eacute;coise de la COVID-19 (BQC19). Cases were considered Omicron cases as more than 85% were estimated to be attributable to Omicron variant during that period. Adults with polymerase chain reaction (PCR)-confirmed COVID-19 were recruited at least 4 weeks after the onset of infection.Results: Of 1,338 individuals contacted, 290 (21.7%) participants were recruited in BQC19 during that period. Median duration between the initial PCR test and follow-up was 44 days (IQR 31-56 d). A total of 137 (47.2%) participants reported symptoms at least 1-month post-infection. The majority (98.6%) had a history of mild COVID-19 illness. Most common persistent symptoms included fatigue (48.2%), shortness of breath (32.6%), and cough (24.1%). Number of symptoms during acute COVID-19 was identified as a risk factor for post-COVID-19 symptoms (OR 1.07 [95% CI 1.03% to 1.10%] p = 0.009).Conclusions: This is the first study reporting the prevalence of post-COVID-19 symptoms associated with Omicron in Canada. These findings will have important implications for provincial services planning. Historique : Les sympt & ocirc;mes post-COVID-19 persistants repr & eacute;sentent un fardeau important pour la sant & eacute;. Le variant Omicron s'est propag & eacute; rapidement dans le monde et a infect & eacute; des milliers de personnes, un nombre largement sup & eacute;rieur aux variants qui l'avaient pr & eacute;c & eacute;d & eacute;. Le risque que bon nombre d'entre elles acqui & egrave;rent des sympt & ocirc;mes persistants est un probl & egrave;me sanitaire majeur. La pr & eacute;sente & eacute;tude visait & agrave; d & eacute;terminer la pr & eacute;valence et les facteurs de risques de sympt & ocirc;mes post-COVID-19 li & eacute;s au variant Omicron.M & eacute;thodologie : Les chercheurs ont r & eacute;alis & eacute; une & eacute;tude observationnelle monocentrique & agrave; Qu & eacute;bec, au Canada, entre d & eacute;cembre 2021 et avril 2022. Les participants & eacute;taient des adultes inscrits & agrave; la Biobanque qu & eacute;b & eacute;coise de la COVID-19 (BQC19). Les cas & eacute;taient consid & eacute;r & eacute;s comme d & eacute;couler du variant Omicron parce que plus de 85% & eacute;taient estim & eacute;s y & ecirc;tre attribuables pendant cette p & eacute;riode. Les adultes atteints d'une COVID-19 confirm & eacute;e par un test d'amplification en cha & icirc;ne par polym & eacute;rase (PCR) ont & eacute;t & eacute; recrut & eacute;s au moins quatre semaines apr & egrave;s l'apparition de l'infection.R & eacute;sultats : Des 1 338 personnes contact & eacute;es, 290 (21,7%) ont & eacute;t & eacute; recrut & eacute;es dans la BQC19 pendant cette p & eacute;riode. La p & eacute;riode moyenne entre le test PCR initial et le suivi & eacute;tait de 44 jours (& Eacute;IQ: de 31 & agrave; 56 jours). Au total, 137 participants (47,2%) ont d & eacute;clar & eacute; des sympt & ocirc;mes au moins un mois apr & egrave;s l'infection. La majorit & eacute; avait & eacute;t & eacute; atteinte d'une COVID-19 l & eacute;g & egrave;re. Les sympt & ocirc;mes les plus persistants & eacute;taient la fatigue (48,2%), l'essoufflement (32,6%) et la toux (24,1%). Il a & eacute;t & eacute; & eacute;tabli que le nombre de sympt & ocirc;mes pendant la COVID-19 aigu & euml; (rapport de cotes: 1,07, IC & agrave; 95% 1,03% & agrave; 1,10%; p = 0,009) & eacute;tait un facteur de risque de sympt & ocirc;mes post-COVID-19.Conclusions : La pr & eacute;sente & eacute;tude est la premi & egrave;re & agrave; rendre compte de la pr & eacute;valence de sympt & ocirc;mes post-COVID-19 associ & eacute;s au variant Omicron au Canada. Ces observations auront des cons & eacute;quences importantes pour la planification des services provinciaux.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 50 条
  • [31] Immediate reinfection with Omicron variant after clearance of a previous SARS-CoV-2 infection
    Mencacci, Antonella
    Gili, Alessio
    Camilloni, Barbara
    Bicchieraro, Giulia
    Spaccapelo, Roberta
    Bietta, Carla
    Stracci, Fabrizio
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2022, 15 (09) : 983 - 985
  • [32] High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022
    Groenheit, Ramona
    Bacchus, Philip
    Galanis, Ilias
    Sonden, Klara
    Bujila, Ioana
    Efimova, Tatiana
    Garli, Fredrik
    Lindsjo, Oskar Karlsson
    Mansjo, Mikael
    Movert, Elin
    Pettke, Aleksandra
    Rapp, Marie
    Sperk, Maike
    Soderholm, Sandra
    Asin, Karin Valentin
    Zanetti, Sarah
    Karlberg, Maria Lind
    Brave, Andreas
    Blom, Kim
    Klingstrom, Jonas
    EMERGING INFECTIOUS DISEASES, 2023, 29 (06) : 1240 - 1243
  • [33] SARS-CoV-2 neutralising antibody response to bivalent booster after omicron infection
    Springer, David N.
    Medits, Iris
    Weseslindtner, Lukas
    Stiasny, Karin
    Aberle, Judith H.
    LANCET MICROBE, 2024, 5 (01): : E8 - E8
  • [34] Incidence of SARS-CoV-2 infection among unvaccinated US adults during the Omicron wave
    Alejo, Jennifer L.
    Chiang, Teresa P. Y.
    Mitchell, Jonathan
    Abedon, Aura T.
    Jefferis, Alexa A.
    Werbel, William
    Massie, Allan B.
    Makary, Martin A.
    Segev, Dorry L.
    JOURNAL OF INTERNAL MEDICINE, 2022, 292 (06) : 965 - 968
  • [35] Reduced risk for Omicron SARS-CoV-2 infection observed in older adults with hybrid immunity
    Pallett, Scott J. C.
    Heskin, Jospeh
    Keating, Fergus
    Tuck, Jeremy
    Mazzella, Andrea
    Randell, Paul
    Rayment, Micahel
    Jones, Rachael
    Mughal, Nabeela
    Davies, Gary W.
    O'Shea, Matthew K.
    Moore, Luke S. P.
    AGE AND AGEING, 2024, 53 (07)
  • [36] Persistent SARS-CoV-2 infection: significance and implications
    Machkovech, Heather M.
    Hahn, Anne M.
    Wang, Jacqueline Garonzik
    Grubaugh, Nathan D.
    Halfmann, Peter J.
    Johnson, Marc C.
    Lemieux, Jacob E.
    O'Connor, David H.
    Piantadosi, Anne
    Wei, Wanting
    Friedrich, Thomas C.
    LANCET INFECTIOUS DISEASES, 2024, 24 (07): : e453 - e462
  • [37] Clinical Efficacy of Imdevimab/Casirivimab for Persistent Omicron SARS-CoV-2 Infection in Patients with Hematological Malignancies
    Hagihara, Masao
    Hayashi, Hiroyoshi
    Nakashima, Shiori
    Imai, Yui
    Nakano, Hirofumi
    Uchida, Tomoyuki
    Inoue, Morihiro
    Sakai-Tagawa, Yuko
    Ito, Mutsumi
    Yamayoshi, Seiya
    Iwatsuki-Horimoto, Kiyoko
    Suzuki, Yutaka
    Kawaoka, Yoshihiro
    INTERNAL MEDICINE, 2024, 63 (16) : 2283 - 2287
  • [38] Persistent SARS-CoV-2 infection and the risk for cancer
    Alpalhao, Miguel
    Ferreira, Joao Augusto
    Filipe, Paulo
    MEDICAL HYPOTHESES, 2020, 143
  • [39] Persistent cellular immunity to SARS-CoV-2 infection
    Breton, Gaelle
    Mendoza, Pilar
    Hagglof, Thomas
    Oliveira, Thiago Y.
    Schaefer-Babajew, Dennis
    Gaebler, Christian
    Turroja, Martina
    Hurley, Arlene
    Caskey, Marina
    Nussenzweig, Michel C.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2021, 218 (04):
  • [40] The Rising Prevalence of SARS-CoV-2 Infection May Not be Due to Young Adults
    Allan-Blitz, Lao-Tzu
    Hertlein, Fred
    Turner, Isaac
    Klausner, Jeffrey D.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2021, 40 (05) : E213 - E214